Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Practice Parameter:Immunotherapy for Guillain-Barre Syndrome, Report of the Quality Standards Subcommittee of the American Academy of Neurology
Neurol 61:736-740, Hughes,R.A.C.,et al, 2003
Course and Treatment of Myasthenia Gravis During Pregnancy
Neurol 52:447-452, Batocchi,A.P.,et al, 1999
Outcome in Severe Pediatric Guillain-Barre Syndrome after Immunotherapy or Supportive Care
Neurol 52:1494-1497, Graf,W.D.,et al, 1999
Acute Neuromuscular Respiratory Paralysis
JNNP 56:334-343, Hughes,R.A.C.&Bihari,D., 1993
Controlled Trial of Plasma Exchange and Leukapheresis in Polymyositis and Dermatomyositis
NEJM 326:1380-1384, Miller,F.W.,et al, 1992
Guillain-Barre Syndrome and Plasmapheresis in Childhood
(Letters) , Ann Neurol 29:688-68991., , 1991
Plasmapheresis in Children with Guillain-Barre Syndrome
Neurol 41:1928-1931, Lamont,P.J.,et al, 1991
Myasthenia Gravis in Mothers and Their Newborns
Clin Obstet Gynecol 34:82-99, Plauche,W.C., 1991
The Role of Plasmapheresis in Childhood Guillain-Barre Syndrome
Ann Neurol 28:65-69, Epstein,M.A.&Sladky,J.T., 1990
Plasmapheresis for Myasthenic Crisis in a Young Child
J Pediatr 110:740-742, Snead,O.C.III.,et al, 1987
Plasmapheresis in Idiopathic Inflammatory Myopathy Experience With 35 Patients
Arch Neurol 38:544-552, Dau,P.C., 1981
Myasthenia Gravis
NEJM 298:136, Drachman,D.B., 1978